Zhuhai Rundu Pharmaceutical (SHE:002923) obtained a drug registration certificate from China's National Medical Products Administration for moxifloxacin hydrochloride tablets, according to a Shenzhen bourse disclosure on Friday.
The pharmaceutical company will be able to produce the drug, which is used to treat acute bacterial sinusitis, acute exacerbation of chronic bronchitis, pneumonia, skin infections and other conditions.
The company's shares closed over 1% lower.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments